Holding an exclusive license Brown University for a proprietary protein micronization and encapsulation process, employing this process, Therapyx has developed a unique second-generation platform technology, EXStaM (patent pending) that allows commercial scale microencapsulation of therapeutic proteins. Methods and selection patents that protect specific products in specific indications have either been licensed, awarded, or are currently pending including the applications covering our general scale-up methods that allow the consistent production of large batches of commercial-grade drug product. Using a novel technology platform (EXStaM) for oral or mucosal delivery, Therapyx has developed a sustained-release microparticulate immune-modulatory biologics using a novel technology platform (EXStaM) for oral or mucosal delivery. The firm's products are geared toward the prevention and treatment of infection, immune-mediated inflammatory diseases, and cancer - the most advanced being NGoXIM for treatment/prevention of gonorrheae and TreXTAM for the treatment of Crohns disease and Lupus.
